Favipiravir (T-705; 6-fluoro-3-hydroxy-2-
pyrazinecarboxamide) is an
antiviral drug that selectively inhibits the
RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular
enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Its
antiviral effect is attenuated by the addition of
purine nucleic acids, indicating the
viral RNA polymerase mistakenly recognizes
favipiravir-RTP as a
purine nucleotide.
Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits
influenza strains resistant to current
antiviral drugs, and shows a synergistic effect in combination with
oseltamivir, thereby expanding
influenza treatment options. A Phase III clinical evaluation of
favipiravir for
influenza therapy has been completed in Japan and two Phase II studies have been completed in the United States. In addition to its anti-
influenza activity,
favipiravir blocks the replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde); phleboviruses (
Rift Valley fever,
sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava, and Prospect Hill); flaviviruses (
yellow fever and West Nile); enteroviruses (
polio- and rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory syncytial virus; and noroviruses. With its unique mechanism of action and broad range of
antiviral activity,
favipiravir is a promising
drug candidate for
influenza and many other
RNA viral diseases for which there are no approved
therapies.